Hopital Saint Joseph

The department is conducting studies on a range of cancers, including head and neck cancer, colon carcinoma, and hepatocellular carcinoma, aiming to test new therapeutic combinations and improve survival outcomes.

• Evaluation of immunotherapy plus targeted agents
• Adjuvant treatment after surgical resection
• Radiation‑based strategies for locally advanced disease

Hopital Saint Joseph hosts 17 active trials with 40 investigators, focusing on innovative cancer care for patients in Marseille and beyond.

Research at the site addresses heart health by investigating therapies for atherosclerotic cardiovascular disease and elevated lipoprotein(a), with the goal of lowering cardiovascular events.

• Lipoprotein(a)‑targeted antisense therapy
• Prevention of myocardial infarction and coronary death
• Assessment of long‑term safety of novel agents

The hospital’s cardiovascular program integrates clinical research into routine care, offering patients access to cutting‑edge treatments.

Trials focus on liver‑related metabolic disorders such as Non‑alcoholic steatohepatitis and Metabolic Dysfunction‑Associated Steatohepatitis, as well as advanced hepatocellular carcinoma, to evaluate disease‑modifying therapies and improve liver function.

• Fibrosis regression with novel agents
• Combination of autophagy inhibitors and immunotherapy
• First‑line systemic options for unresectable liver cancer

With a multidisciplinary team, the site enrolls patients in studies that target both metabolic pathways and tumor control.

The clinic evaluates new treatments for chronic skin conditions including Atopic Dermatitis and Hidradenitis Suppurativa, seeking faster symptom relief and better quality of life.

• Biologic agents targeting inflammatory pathways
• Patient‑reported outcome measures of disease severity
• Long‑term safety and efficacy in moderate‑to‑severe cases

These dermatology studies provide regional patients with access to therapies not yet widely available.

A focused investigation on Mycobacterium xenopi pulmonary infection aims to improve eradication rates using innovative inhaled antibiotic formulations.

• Comparison of liposomal inhaled therapy versus standard regimen
• Measurement of sputum conversion at three months
• Safety monitoring of respiratory adverse events

The infectious disease team collaborates closely with pulmonology to bring these trials to patients with difficult‑to‑treat lung infections.

Clinical work includes studies on gastrointestinal cancers such as small bowel adenocarcinoma and resectable colon carcinoma, evaluating pre‑operative chemotherapy and surgical outcomes.

• Neoadjuvant chemotherapy protocols for elderly patients
• Impact of treatment sequencing on recurrence‑free survival
• Biomarker‑driven personalization of therapy

By integrating trial data with routine gastroenterology practice, Hopital Saint Joseph advances care for complex digestive tract malignancies.